Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer ; volume:29 ; number:11-12 ; day:12 ; month:10 ; year:2024 ; pages:2047-2073 ; date:12.2024
Apoptosis ; 29, Heft 11-12 (12.10.2024), 2047-2073, 12.2024
- Urheber
-
Sethy, Bidyadhar
Upadhyay, Richa
Narwanti, Iin
Yu, Zih-Yao
Lee, Sung-Bau
Liou, Jing-Ping
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10495-024-02023-7
- URN
-
urn:nbn:de:101:1-2501272107152.670020476125
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sethy, Bidyadhar
- Upadhyay, Richa
- Narwanti, Iin
- Yu, Zih-Yao
- Lee, Sung-Bau
- Liou, Jing-Ping
- SpringerLink (Online service)
Ähnliche Objekte (12)
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention